AstraZeneca, Pfizer Agree Rare-Disease Deal
Wall Street Journal
AstraZeneca’s Alexion unit has completed a purchase and license agreement for an early-stage rare-disease gene therapy portfolio from Pfizer for $1 billion.
https://www.wsj.com/articles/astrazenecas-rare-disease-unit-buy-pfizer-portfolio-for-1-bln-6fec24fb